Pharmacological Actions of NGB 2904, a Selective Dopamine D3 Receptor Antagonist, in Animal Models of Drug Addiction (original) (raw)

ABSTRACT

As a continuation of our work with SB‐277011A, we have examined the effects of another highly elective dopamine (DA) D3 receptor antagonist, N‐(4‐[4‐{2,3‐dichlorophenyl}‐1‐piperazinyl]butyl)‐2‐fluorenylcarboxamide (NGB 2904), in animal models of addiction. Our results indicate that by systemic administration, NGB 2904 inhibits intravenous cocaine self‐administration maintained under a progressive‐ratio (PR) reinforcement schedule, cocaine‐ or cocaine cue–induced reinstatement of cocaine‐seeking behavior, and cocaine‐ or other addictive drug‐enhanced brain stimulation reward (BSR). The action of NGB 2904 on PR cocaine self‐administration was long‐lasting (1–2 days) after a single injection, supporting its potential use in treatment of cocaine addiction. The effects of NGB 2904 in the BSR paradigm were dose‐dependent for both NGB 2904 and cocaine; that is, only lower doses of NGB 2904 were effective, and their putative antiaddiction effect could be overcome by increasing the doses of cocaine or other addictive drugs. A dopamine‐dependent mechanism is proposed to explain the effects of NGB 2904 on cocaine's actions in these animal models of drug addiction. The data reviewed in this paper suggest that NGB 2904 or other D3‐selective antagonists may have potential in controlling motivation for drug‐taking behavior or relapse to drug‐seeking behavior, but may have a limited role in antagonizing the acute rewarding effects produced by cocaine or other addictive drugs. In addition, NGB 2904 may also act as a useful tool to study the role of D3 receptors in drug addiction.

Keywords: Antiaddiction drugs, Cocaine, D3 antagonists, D3 receptors, Dopamine, Drug addiction, NGB 2904, SB‐277011A

Full Text

The Full Text of this article is available as a PDF (1.2 MB).

Acknowledgments

Acknowledgment This work was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health. The NGB 2904 used in the work described herein was synthesized in the Medicinal Chemistry Section, Intramural Research Program, National Institute on Drug Abuse, according to the methods described in Yuan et al. 1998. We thank Dr. Amy Hauck Newman for supplying compounds and for constructive criticisms regarding this manuscript.

The authors have no conflict of interest.

REFERENCES

  1. Austin NE, Baldwin SJ, Cutler L, Deeks N, Kelly PJ, Nash M, Shardlow CE, Stemp G, Thewlis K, Ayrton A, et al. (2001) Pharmacokinetics of the novel, high affinity and selective dopamine D3 receptor antagonist SB‐277011 in rat, dog and monkey: In vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 31:677‐686. [DOI] [PubMed] [Google Scholar]
  2. Bardo MT (1998) Neuropharmacological mechanisms of drug reward: Beyond dopamine in the nucleus accumbens. Crit Rev Neurobiol 12:37‐67. [DOI] [PubMed] [Google Scholar]
  3. Bauco P, Wise RA (1997) Synergistic effects of cocaine with lateral hypothalamic brain stimulation reward: Lack of tolerance or sensitization. J Pharmacol Exp Ther 283:1160‐1167. [PubMed] [Google Scholar]
  4. Boeckler F, Gmeiner P (2006) The structural evolution of dopamine D3 receptor ligands: Structure‐activity relationships and selected neuropharmacological aspects. Pharmacol Ther 112:281‐333. [DOI] [PubMed] [Google Scholar]
  5. Bressan RA, Crippa JA (2005) The role of dopamine in reward and pleasure behaviour—review of data from preclinical research. Acta Psychiatr Scand 111(suppl 437)427:14‐21. [DOI] [PubMed] [Google Scholar]
  6. Caine SB, Koob GF (1993) Modulation of cocaine self‐administration in the rat through D‐3 dopamine receptors. Science 260:1814‐1816. [DOI] [PubMed] [Google Scholar]
  7. Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, et al. (2003) Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: Inihibition of cocaine‐seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem 46:3822‐3839. [DOI] [PubMed] [Google Scholar]
  8. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH (2005) Dopamine agonist‐induced yawning in rats: A dopamine D3 receptor‐mediated behavior. J Pharmacol Exp Ther 314:310‐319. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue‐controlled cocaine‐seeking by a selective D3 dopamine receptor antagonist SB‐277011‐A. Neuropsychopharmacology 28:329‐338. [DOI] [PubMed] [Google Scholar]
  10. Diaz J, Pilon C, Le Foll B, Gros C, Triller A, Schwartz J‐C, Sokoloff P (2000) Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J Neurosci 20:8677‐8684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Drago J, Padungchaichot P, Accili D, Fuchs S (1998) Dopamine receptors and dopamine transporter in brain function and addictive behaviors: Insights from targeted mouse mutants. Dev Neurosci 20:188‐203. [DOI] [PubMed] [Google Scholar]
  12. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiebot M‐H (2003) Effects of a dopamine D3 receptor ligand, BP897, on acquisition and expression of food‐, morphine and cocaine‐induced conditioned place preference, and food‐seeking behavior in rats. Neuropsychopharmacology 28:1903‐1915. [DOI] [PubMed] [Google Scholar]
  13. Duaux E, Gorwood P, Griffon N, Bourdel M‐C, Sautel F, Sokoloff P, Schwartz J‐C, Ades J, Lôo H, Poirier M‐F (1998) Homozygosity at the dopamine D3 receptor gene is associated with opiate dependence. Mol Psychiatry 3:333‐336. [DOI] [PubMed] [Google Scholar]
  14. Gál K, Gyertyán I (2003) Targeting the dopamine D(3) receptor cannot influence continuous reinforcement cocaine self‐administration in rats. Brain Res Bull 6:595‐601. [DOI] [PubMed] [Google Scholar]
  15. Garcia‐Ladona FJ, Cox BF (2003) BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine‐addiction. CNS Drug Rev 9:141‐158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Gardner EL (1999) The neurobiology and genetics of addiction: Implications of “reward deficiency syndrome” for therapeutic strategies in chemical dependency In Elster J. (Ed), _Addiction: Entries and Exits._New York : Russell Sage Foundation, pp 57‐119. [Google Scholar]
  17. Gardner EL (2000) What we have learned about addiction from animal models of drug self‐administration. Am J Addict 9:285‐313. [DOI] [PubMed] [Google Scholar]
  18. Gardner EL (2005) Brain reward mechanisms In Lowinson JH, Ruiz P, Millman RB, Langrod JG. (Eds), Substance Abuse: A Comprehensive Textbook, 4th ed Philadelphia : Lippincott Williams & Wilkins, pp 48‐97. [Google Scholar]
  19. Gardner EL, Spiller K, Xi ZX, Peng XQ, Li X, Dillon C, Ashby CR Jr, Heidbreder CA (2007) The putative dopamine D3 receptor antagonists SB‐277011A, NGB2904, S33138 or BP897 attenuate methamphetamine‐enhanced brain stimulation reward in rats. College on Problems of Drug Dependence, Abstract.
  20. Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng X‐Q, Xi Z‐X (2005) Acute administration of SB‐277011A, NGB 2904, or BP 897 inhibits cocaine cue‐induced reinstatement of drug‐seeking behavior in rats: Role of dopamine D3 receptors. Synapse 57:17‐28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Girault J‐A, Greengard P (2004) The neurobiology of dopamine signaling. Arch Neurol 61:641‐644. [DOI] [PubMed] [Google Scholar]
  22. Gorelick DA, Gardner EL, Xi Z‐X (2004) Agents in development for the management of cocaine abuse. Drugs 64:1547‐1573. [DOI] [PubMed] [Google Scholar]
  23. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (2005) Novel heterocyclic trans olefin analogues of _N_‐{4‐[4‐(2,3‐dichlorophenyl)piperazin‐1‐yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839‐848. [DOI] [PubMed] [Google Scholar]
  24. Gyertyán I, Gál K (2003) Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine‐induced place preference. Neuroreport 14:93‐98. [DOI] [PubMed] [Google Scholar]
  25. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective dopamine D1 antagonist, on smoked cocaine self‐administration by humans. Psychopharmacology 155:330‐337. [DOI] [PubMed] [Google Scholar]
  26. Heidbreder CA, Gardner EL, Xi Z‐X, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr. (2005) The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Brain Res Rev 49:77‐105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Joyce JN, Millan MJ (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10:917‐925. [DOI] [PubMed] [Google Scholar]
  28. Kalivas PW, Volkow ND (2005) The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 162:1403‐1413. [DOI] [PubMed] [Google Scholar]
  29. Kapur S, Mamo D (2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081‐1090. [DOI] [PubMed] [Google Scholar]
  30. Kornetsky C (2004) Brain‐stimulation reward, morphine‐induced oral stereotypy, and sensitization: Implications for abuse. Neurosci Biobehav Rev 27:777‐786. [DOI] [PubMed] [Google Scholar]
  31. Kostrzewa RM, Brus R, Rykaczewska M, Plech A (1993) Low‐dose quinpirole ontogenically sensitizes to quinpirole‐induced yawning in rats. Pharmacol Biochem Behav 44:487‐489. [DOI] [PubMed] [Google Scholar]
  32. Kuhar MJ, Pilotte NS (1996) Neurochemical changes in cocaine withdrawal. Trends Pharmacol Sci 17:260‐264. [DOI] [PubMed] [Google Scholar]
  33. Kurashima M, Yamada K, Nagashima M, Shirakawa K, Furukawa T (1995) Effects of putative dopamine D3 receptor agonists, 7‐OH‐DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav 52:503‐508. [DOI] [PubMed] [Google Scholar]
  34. Le Foll B, Goldberg SR, Sokoloff P (2005) The dopamine D3 receptor and drug dependence: Effects on reward or beyond? Neuropharmacology 49:525‐541. [DOI] [PubMed] [Google Scholar]
  35. Levant B (1997) The D3 dopamine receptor: Neurobiology and potential clinical relevance. Pharmacol Rev 49:231‐252. [PubMed] [Google Scholar]
  36. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, Nader MA (2007) Effects of two novel D3‐selective compounds, NGB 2904 and CJB 090, on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther [Epub ahead of print]. [DOI] [PubMed] [Google Scholar]
  37. Mateo Y, Lack CM, Morgan D, Roberts DCS, Jones SR (2005) Reduced dopamine terminal function and insensitivity to cocaine following cocaine binge self‐administration and deprivation. Neuropsychopharmacology 30:1455‐1463. [DOI] [PubMed] [Google Scholar]
  38. Narita M, Mizuo K, Mizoguchi H, Sakata M, Narita M, Tseng LF, Suzuki T (2003) Molecular evidence for the functional role of dopamine D3 receptor in the morphine‐induced rewarding effect and hyperlocomotion. J Neurosci 23:1006‐1012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Neisewander JL, Fuchs RA, Tran‐Nguyen LTL, Weber SM, Coffey GP, Joyce JN (2004) Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self‐administration: Implications for cocaine‐seeking behavior. Neuropsychopharmacology 29:1479‐1487. [DOI] [PubMed] [Google Scholar]
  40. Neisewander JL, O'Dell LE, Tran‐Nguyen LTL, Castañeda E, Fuchs RA (1996) Dopamine overflow in the nucleus accumbens during extinction and reinstatement of cocaine self‐administration behavior. Neuropsychopharmacology 15:506‐514. [DOI] [PubMed] [Google Scholar]
  41. Newman AH, Cao J, Bennett CJ, Robarge MJ, Freeman RA, Luedtke RR (2003) _N_‐{4‐[4‐(2,3‐dichlorophenyl)piperazin‐1‐yl]butyl, butenyl and butynyl}arylcarboxamides as novel dopamine D3 receptor antagonists. Bioorg Med Chem Lett 13:2179‐2183. [DOI] [PubMed] [Google Scholar]
  42. Newman AH, Grundt P, Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48:3663‐3679. [DOI] [PubMed] [Google Scholar]
  43. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K (2001) Risperidone pre‐treatment reduces the euphoric effects of experimentally administered cocaine. Psychiatry Res 102:227‐233. [DOI] [PubMed] [Google Scholar]
  44. O'Brien CP (2003) Research advances in the understanding and treatment of addiction. Am J Addict 12(Suppl 2):S36‐S47. [PubMed] [Google Scholar]
  45. O'Brien CP, Gardner EL (2005) Critical assessment of how to study addiction and its treatment: Human and non‐human animal models. Pharmacol Ther 108:18‐58. [DOI] [PubMed] [Google Scholar]
  46. Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi Z‐X, Gardner EL (2006) The selective dopamine D3 receptor antagonist SB‐277011A reduces nicotine‐enhanced brain reward and nicotine‐paired environmental cue functions. Int J Neuropsychopharmacol 9:585‐602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Pierce RC, Kumaresan V (2006) The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215‐238. [DOI] [PubMed] [Google Scholar]
  48. Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz J‐C, Everitt BJ, Sokoloff P (1999) Selective inhibition of cocaine‐seeking behaviour by a partial dopamine D3 receptor agonist. Nature 400:371‐375. [DOI] [PubMed] [Google Scholar]
  49. Platt DM, Rowlett JK, Spealman RD (2002) Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology 163:265‐282. [DOI] [PubMed] [Google Scholar]
  50. Pritchard LM, Newman AH, McNamara RK, Logue AD, Taylor B, Welge JA, Xu M, Zhang J, Richtand NM (2007) The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine‐stimulated locomotion. Pharmacol. Biochem. Behav. in press. [DOI] [PubMed] [Google Scholar]
  51. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, et al. (2000) Pharmacological actions of a novel, high‐affinity, and selective human dopamine D3 receptor antagonist, SB‐277011‐A. J Pharmacol Exp Ther 294:1154‐1165. [PubMed] [Google Scholar]
  52. Remington G, Kapur S (2001) SB‐277011 GlaxoSmithKline. Curr Opin Investig Drugs 2:946‐949. [PubMed] [Google Scholar]
  53. Richardson NR, Roberts DCS (1996) Progressive ratio schedules in drug self‐administration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 66:1‐11. [DOI] [PubMed] [Google Scholar]
  54. Riddle EL, Fleckenstein AE, Hanson GR (2006) Mechanisms of methamphetamine‐induced dopaminergic neurotoxicity. AAPS J 8:E413‐E418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Robarge MJ, Husbands SM, Kieltyka A, Brodbeck R, Thurkauf A, Newman AH (2001) Design and synthesis of [(2,3‐dichlorophenyl)piperazin‐1‐yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype. J Med Chem 44:3175‐3186. [DOI] [PubMed] [Google Scholar]
  56. Rothman RB, Glowa JR. (1995) A review of the effects of dopaminergic agents on humans, animals, and drug‐seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol Neurobiol 11:1‐19. [DOI] [PubMed] [Google Scholar]
  57. Rowlett JK (2000) A labor‐supply analysis of cocaine self‐administration under progressive‐ratio schedules: Antecedents, methodologies, and perspectives. Psychopharmacology 153:1‐16. [DOI] [PubMed] [Google Scholar]
  58. Shalev U, Grimm JW, Shaham Y (2002) Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacol Rev 54:1‐42. [DOI] [PubMed] [Google Scholar]
  59. Sokoloff P, Diaz J, Le Foll B, Guillin O, Leriche L, Bezard E, Gross C (2006) The dopamine D3 receptor: A therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25‐43. [DOI] [PubMed] [Google Scholar]
  60. Sokoloff P, Le Foll B, Perachon S, Bordet R, Ridray S, Schwartz J‐C (2001) The dopamine D3 receptor and drug addiction. Neurotox Res 3:433‐441. [DOI] [PubMed] [Google Scholar]
  61. Stafford D, LeSage MG, Glowa JR (1998) Progressive‐ratio schedules of drug delivery in the analysis of drug self‐administration: A review. Psychopharmacology 139:169‐184. [DOI] [PubMed] [Google Scholar]
  62. Staley JK, Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100‐6106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Stanwood GD, Artymyshyn RP, Kung M‐P, Kung HF, Lucki I, McGonigle P (2000) Quantitative autoradiographic mapping of rat brain dopamine D3 binding with [125I]7‐OH‐PIPAT: Evidence for the presence of D3 receptors on dopaminergic and nondopaminergic cell bodies and terminals. J Pharmacol Exp Ther 295:1223‐1231. [PubMed] [Google Scholar]
  64. Stemp G, Ashmeade T, Branch CL, Hadley MS, Hunter AJ, Johnson CN, Nash DJ, Thewlis KM, Vong AKK, Austin NE, et al. (2000) Design and synthesis of _trans‐N_‐[4‐[2‐(6‐cyano‐1,2,3,4‐tetrahydroisoquinolin‐2‐yl)ethyl]cyclohexyl]‐4‐quinolinecarboxamide (SB‐277011): A potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 43:1878‐1885. [DOI] [PubMed] [Google Scholar]
  65. Volkow ND, Fowler JS, Wang G‐J (1999) Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J Psychopharmacol 13:337‐345. [DOI] [PubMed] [Google Scholar]
  66. Volkow ND, Wang G‐J, Telang F, Fowler JS, Logan J, Childress A‐R, Jayne M, Ma Y, Wong C (2006) Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. J Neurosci 26:6583‐6588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Vorel SR, Ashby CR Jr, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, Gardner EL (2002) Dopamine D3 receptor antagonism inhibits cocaine‐seeking and cocaine‐enhanced brain reward in rats. J Neurosci 22:9595‐9603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Wicke K, Garcia‐Ladona J (2001) The dopamine D3 receptor partial agonist, BP‐897, is an antagonist at human dopamine D3 receptors and at rat somatodendritic dopamine D3 receptors. Eur J Pharmacol 424:85‐90. [DOI] [PubMed] [Google Scholar]
  69. Wise RA (1996a) Addictive drugs and brain stimulation reward. Annu Rev Neurosci 19:319‐340. [DOI] [PubMed] [Google Scholar]
  70. Wise RA (1996b) Neurobiology of addiction. Curr Opin Neurobiol 6:243‐251. [DOI] [PubMed] [Google Scholar]
  71. Wise RA (2005) Forebrain substrates of reward and motivation. J Comp Neurol 493:115‐121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Wise RA (2006) Role of brain dopamine in food reward and reinforcement. Phil Trans R Soc Lond B Biol Sci 361:1149‐1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Wood MD, Boyfield I, Nash DJ, Jewitt FR, Avenell KY, Riley G (2000) Evidence for antagonist activity of the human dopamine D3 receptor partial agonist, BP 897, at human dopamine D3 receptor. Eur J Pharmacol 407:47‐51. [DOI] [PubMed] [Google Scholar]
  74. Xi Z‐X, Gilbert J, Campos AC, Kline N, Ashby CR Jr, Hagan JJ, Heidbreder CA, Gardner EL (2004) Blockade of mesolimbic dopamine D3 receptors inhibits stress‐induced reinstatement of cocaine‐seeking in rats. Psychopharmacology 176:57‐65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Xi Z‐X, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB‐277011A attenuates cocaine reinforcement as assessed by progressive‐ratio and variable‐cost–variable‐payoff fixed‐ratio cocaine self‐administration in rats. Eur J Neurosci 21:3427‐3438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Xi Z‐X, Newman AH, Gilbert JG, Pak AC, Peng X‐Q, Ashby CR Jr, Gitajn L, Gardner EL (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine‐induced reinstatement of drug‐seeking behavior in rats. Neuropsychopharmacology 31:1393‐1405. [DOI] [PubMed] [Google Scholar]
  77. You Z‐B, Chen Y‐Q, Wise RA (2001) Dopamine and glutamate release in the nucleus accumbens and ventral tegmental area of rat following lateral hypothalamic self‐stimulation. Neuroscience 107:629‐639. [DOI] [PubMed] [Google Scholar]
  78. Yuan J, Chen X, Brodbeck R, Primus R, Braun J, Wasley JWF, Thurkauf A (1998) NGB 2904 and NGB 2849: Two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 8:2715‐2718. [DOI] [PubMed] [Google Scholar]